Al Hammadi Holding Valuation
Is 4007 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4007 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4007 (SAR40.05) is trading below our estimate of fair value (SAR87.27)
Significantly Below Fair Value: 4007 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4007?
Key metric: As 4007 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4007's PE Ratio? | |
|---|---|
| PE Ratio | 19.6x |
| Earnings | ر.س326.23m |
| Market Cap | ر.س6.33b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.5x |
| Enterprise Value/EBITDA | 16x |
| PEG Ratio | 2.1x |
Price to Earnings Ratio vs Peers
How does 4007's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.9x | ||
4009 Middle East Healthcare | 30.6x | 21.4% | ر.س6.5b |
4005 National Medical Care | 26.4x | 11.5% | ر.س7.2b |
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 46.6x | 20.0% | ر.س13.4b |
4004 Dallah Healthcare | 31.9x | 14.2% | ر.س15.0b |
4007 Al Hammadi Holding | 19.6x | 9.4% | ر.س6.4b |
Price-To-Earnings vs Peers: 4007 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the peer average (33.9x).
Price to Earnings Ratio vs Industry
How does 4007's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4007 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the Asian Healthcare industry average (21.1x).
Price to Earnings Ratio vs Fair Ratio
What is 4007's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19.6x |
| Fair PE Ratio | 24.8x |
Price-To-Earnings vs Fair Ratio: 4007 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the estimated Fair Price-To-Earnings Ratio (24.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س40.05 | ر.س53.00 +32.3% | 7.4% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Nov ’25 | ر.س39.95 | ر.س53.00 +32.7% | 7.4% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Oct ’25 | ر.س42.55 | ر.س53.00 +24.6% | 7.4% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Sep ’25 | ر.س44.90 | ر.س53.87 +20.0% | 6.8% | ر.س61.00 | ر.س48.00 | n/a | 8 |
| Aug ’25 | ر.س46.05 | ر.س57.65 +25.2% | 6.5% | ر.س64.00 | ر.س54.00 | n/a | 8 |
| Jul ’25 | ر.س45.80 | ر.س57.69 +26.0% | 6.1% | ر.س64.00 | ر.س54.00 | n/a | 9 |
| Jun ’25 | ر.س48.25 | ر.س59.53 +23.4% | 6.9% | ر.س66.00 | ر.س54.00 | n/a | 8 |
| May ’25 | ر.س56.30 | ر.س59.36 +5.4% | 9.0% | ر.س68.00 | ر.س52.00 | n/a | 9 |
| Apr ’25 | ر.س56.90 | ر.س60.02 +5.5% | 8.6% | ر.س68.00 | ر.س52.00 | n/a | 9 |
| Mar ’25 | ر.س66.90 | ر.س60.63 -9.4% | 8.5% | ر.س68.00 | ر.س52.00 | n/a | 8 |
| Feb ’25 | ر.س61.80 | ر.س57.75 -6.6% | 6.3% | ر.س64.00 | ر.س52.00 | n/a | 8 |
| Jan ’25 | ر.س60.20 | ر.س57.00 -5.3% | 8.9% | ر.س64.00 | ر.س46.00 | n/a | 8 |
| Dec ’24 | ر.س57.00 | ر.س55.75 -2.2% | 8.4% | ر.س61.00 | ر.س46.00 | n/a | 8 |
| Nov ’24 | ر.س52.90 | ر.س56.75 +7.3% | 13.4% | ر.س73.00 | ر.س45.00 | ر.س39.95 | 8 |
| Oct ’24 | ر.س53.00 | ر.س56.86 +7.3% | 14.0% | ر.س73.00 | ر.س45.00 | ر.س42.55 | 7 |
| Sep ’24 | ر.س53.80 | ر.س56.63 +5.3% | 13.2% | ر.س73.00 | ر.س45.00 | ر.س44.90 | 8 |
| Aug ’24 | ر.س59.00 | ر.س54.31 -7.9% | 17.2% | ر.س73.00 | ر.س42.00 | ر.س46.05 | 7 |
| Jul ’24 | n/a | ر.س54.31 0% | 17.2% | ر.س73.00 | ر.س42.00 | ر.س45.80 | 7 |
| Jun ’24 | ر.س52.20 | ر.س50.49 -3.3% | 11.8% | ر.س58.00 | ر.س42.00 | ر.س48.25 | 7 |
| May ’24 | ر.س53.80 | ر.س50.06 -6.9% | 10.9% | ر.س55.00 | ر.س42.00 | ر.س56.30 | 7 |
| Apr ’24 | ر.س48.75 | ر.س47.92 -1.7% | 12.6% | ر.س55.00 | ر.س40.00 | ر.س56.90 | 7 |
| Mar ’24 | ر.س48.00 | ر.س46.35 -3.4% | 10.5% | ر.س53.95 | ر.س40.00 | ر.س66.90 | 7 |
| Feb ’24 | ر.س48.00 | ر.س46.35 -3.4% | 10.5% | ر.س53.95 | ر.س40.00 | ر.س61.80 | 7 |
| Jan ’24 | ر.س41.00 | ر.س44.89 +9.5% | 8.5% | ر.س53.00 | ر.س40.00 | ر.س60.20 | 7 |
| Dec ’23 | ر.س43.20 | ر.س43.92 +1.7% | 11.5% | ر.س53.00 | ر.س35.25 | ر.س57.00 | 7 |
| Nov ’23 | ر.س44.35 | ر.س41.14 -7.2% | 9.6% | ر.س46.00 | ر.س35.25 | ر.س52.90 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.